Welcome to our dedicated page for Greater Cannabis SEC filings (Ticker: GCAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to untangle Greater Cannabis’s multilayered cannabis and biotech disclosures can feel daunting. Each 10-K spans detailed R&D data on its transmucosal delivery platform, while every 8-K captures shifting regulatory landscapes across state and federal lines. Add insider moves and you have a document set that’s anything but straightforward.
Stock Titan solves that complexity. Our AI reads every Greater Cannabis annual report 10-K simplified, flags licensing milestones in the quarterly earnings report 10-Q filing, and sends real-time alerts the moment a Greater Cannabis Form 4 insider transactions real-time notice appears. Need to track executive stock sales? Type “Greater Cannabis insider trading Form 4 transactions” and jump straight to the numbers. Curious about upcoming shareholder votes? We link you to the Greater Cannabis proxy statement executive compensation tables and translate legal prose into plain language. Material event just dropped? The Greater Cannabis 8-K material events explained section highlights how new regulations might impact revenue streams.
Beyond raw documents, you’ll find concise AI-powered summaries, side-by-side quarter comparisons, and keyword search that actually recognizes natural questions like “understanding Greater Cannabis SEC documents with AI” or “Greater Cannabis earnings report filing analysis.” From Greater Cannabis executive stock transactions Form 4 to pipeline disclosures, every filing is indexed, time-stamped, and ready for immediate review—no EDGAR maze required.
The Greater Cannabis Company (GCAN) filed its Q3 2025 report. The company generated $0 revenue and reported a net loss of $36,099 for the quarter. For the nine months ended September 30, 2025, net loss was $669,369.
As of September 30, 2025, cash was $21,355 against $1,129,697 in current liabilities, resulting in a stockholders’ deficit of $(1,108,342). Management disclosed substantial doubt about the company’s ability to continue as a going concern.
The company completed a 1-for-1,500 reverse stock split in October 2025; shares outstanding were 900,256 as of September 30, 2025, and 944,935 as of October 22, 2025. During 2025, the FirstFire note accrued $306,323 in default penalties and interest; an amendment provides the note is deemed satisfied upon completion of the reverse split. On October 22, 2025, GCAN created Series B Convertible Preferred (1,000 shares), issuing it to the CEO in exchange for $20,000 of waived compensation; these shares carry 51.0% voting power.
The Greater Cannabis Company (GCAN) created a new Series B Convertible Preferred Stock and issued it to CEO Aitan Zacharin in exchange for waiving
Each Series B share is convertible at the holder’s option into common stock at a rate of 100,000 common shares per preferred share, subject to customary adjustments for stock splits or combinations. The super‑voting rights terminate if any Series B is converted in part or transferred to a third party, after which the shares vote on an as‑converted basis with other classes. The Series B has no dividend rights and a liquidation preference of $0.001 per share.
The Greater Cannabis Company (GCAN) amended its report to update timing for a reverse stock split. A 1-for-1,500 reverse split is effective as of the close of business on October 16, 2025, after a one-day delay due to a FINRA Daily List omission.
The stock will trade on a post-split basis starting October 17, 2025, under ticker GCAND for twenty trading days, with new CUSIP 391657202. Issued and outstanding common shares will be reduced from 1,349,888,436 to approximately 900,256. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole share. Authorized shares and the $0.001 par value are unchanged. The split also applies to shares issuable upon conversion of outstanding convertible debt, warrants, and options.
The Greater Cannabis Company (GCAN) is implementing a 1-for-1,500 reverse stock split of its common stock, effective as of the close of business on October 15, 2025. The stock will begin trading on a post-split basis on October 16, 2025 under the temporary ticker GCAND for twenty trading days, with a new CUSIP 391657202.
The reverse split reduces issued and outstanding common shares from 1,349,888,436 to approximately 900,256. No fractional shares will be issued; holders entitled to a fraction will receive one whole share. The action also applies to shares issuable upon conversion of outstanding convertible debt, warrants, and options. Authorized shares and par value ($0.001) remain unchanged, and the company notes it will have additional shares available for potential future issuance, without specific plans beyond honoring existing convertible and equity awards.
FAQ
What is the current stock price of Greater Cannabis (GCAN)?
What is the market cap of Greater Cannabis (GCAN)?
